R. Stephanie Huang, PhD

Co-Leader, Genetic Mechanisms Program

United States

Contact Dr. Huang: rshuang@umn.edu

Dr. R. Stephanie Huang is a Tenured Professor at the Department of Experimental and Clinical Pharmacology, University of Minnesota. She is also an Associate Director for the Institute of Personalized Medicine and a Co-Chair of the Genetic Mechanism Program within the Masonic Cancer Center at the University of Minnesota. She is a Chair of the International Pharmaceutical Federation (FIP) Special Interest Group on Personalised and Precision Medicine and a Chair for the Oncology Special Interest Group within the Pharmacogenomics Global Research Network (PGRN). She serves on the editorial board of Annals of Translational Medicine and Frontiers in Pharmacology. To date, she has published over 100 peer-reviewed research papers many of which are in high caliber journals, e.g., Nature, Nature Medicine, PNAS, Blood, Cancer Research, Genome Biology and American Journal of Human Genetics. Dr. Huang is a board certified clinical pharmacologist with extensive training in genetics, molecular and cell biology, clinical trials and high throughput data analysis.


PhD in Clinical Pharmacology from Purdue University in 2005.

Expand all


Research Summary/Interests

The Huang laboratory’s main research focus is translational pharmacogenomics with particular interest in the pharmacogenomics of anti-cancer agents. By systematically evaluating human genome and its relationships to drug response and toxicity, their goal is to develop clinically useful models that predict risks for adverse drug reactions and non-response prior to administration of chemotherapy. With her broad training background, Dr. Huang assembles and leads a multi-disciplinary team that consists of computational biologist, geneticist, pharmacist/pharmacologist, physician, molecular biologist and biostatistician to tackle a series of serious problems in cancer research. These include the lack of mechanistic understanding of genomic regulation of cancer phenotypes; the lack of reproducible predictive biomarkers for cancer therapeutic agents; and the lack of effective treatment for many hard to treat cancers.

More information about the Huang lab can be found online at http://huang-lab.umn.edu